Merck is licensing alimatravir before Phase 3 ends. Can a monthly HIV pill beat the access clock?
Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.
Pharma & Biotech
Pharma & Biotech
Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.